CRISPR Therapeutics shares steady as Barclays maintains rating

CRISPR Therapeutics (CRSP) presented promising early Phase 1 data for its CTX310 cholesterol drug, demonstrating significant peak reductions of up to 82% in triglycerides and 86% in LDL in a single patient at the highest dose, though its CTX320 program's data release is now delayed to H1 2026. Analyst sentiment is mixed, with Barclays maintaining an Equalweight rating and $42 price target, contrasting with William Blair and Citizens JMP reiterating Outperform ratings, the latter at an $86 target. The company continues to advance preclinical programs and expand through a new siRNA partnership, as the stock has seen a 16% return over six months.

Analysis

CRISPR Therapeutics (CRSP) is presenting a mixed but cautiously optimistic clinical and strategic picture. The company reported positive, though very early, Phase 1 data for its in vivo cholesterol treatment, CTX310, demonstrating peak triglyceride and LDL reductions of up to 82% and 86% respectively in a single patient at the highest dose, with a consistent safety profile. However, this positive development is counterbalanced by a significant delay in its CTX320 program, with the Phase 1 update now pushed to H1 2026 from Q2 2025, introducing timeline uncertainty. This news has elicited a divided response from analysts; Barclays maintained an Equalweight rating with a $42 price target, while William Blair and Citizens JMP reiterated Outperform ratings, the latter with an $86 target, highlighting a wide valuation divergence. The company is also actively pursuing growth through partnerships, such as a new collaboration with Sirius Therapeutics for siRNA therapies, and continues to advance its preclinical CTX340 program for hypertension. From a market perspective, the stock has already appreciated 16% over the past six months, and technical signals suggest it may be entering overbought territory, indicating some positive sentiment may already be priced in.

Key Decisions for Investors

• Investors should weigh the promising but very early-stage CTX310 data against the significant clinical trial delay for the CTX320 program, which introduces near-term uncertainty and pushes back a potential value catalyst.
• The wide dispersion in analyst price targets ($42 vs. $86), combined with the stock's recent 16% appreciation and potentially overbought technicals, suggests that caution may be warranted for establishing new positions at current levels.
• Monitor for key de-risking events, particularly the complete Phase 1 data for CTX310 expected in H2 2025, as this will be critical for validating the potency and safety of the company's in vivo platform.
• The strategic partnership to develop siRNA therapies should be viewed as a positive long-term diversifier, potentially mitigating single-platform risk and expanding the company's addressable markets.